Gravity ends Synergy CHC (NASDAQ: SNYR) license for UAE and Turkey

Rhea-AI Filing Summary

Synergy CHC Corp. reported that on February 27, 2026, Gravity Pharma General Trading LLC terminated, ab initio, a Brand License Agreement originally signed on March 31, 2025 and later amended on June 30, 2025. The agreement had granted Gravity an exclusive license to sell and market certain FOCUSfactor and Flat Tummy Co. products in the United Arab Emirates and Turkey in exchange for an aggregate license fee of $2.9 million, which the company had previously recorded as revenue. Despite the termination, Synergy CHC states that it continues to pursue registration and marketing of these products in the same territories.

Insights

Equity research analyst

License termination removes a specific regional partner but leaves product plans intact.

The filing describes Gravity Pharma General Trading LLC terminating, ab initio, a Brand License Agreement covering FOCUSfactor and Flat Tummy Co. products in the UAE and Turkey. The agreement involved an aggregate license fee of $2.9 million that had been recorded as revenue.

This change affects a defined regional distribution and licensing structure rather than the company’s global operations. The company indicates it is continuing to pursue registration and marketing of the same products in the affected territories, suggesting ongoing strategic interest in that market, though under different arrangements.

Key points to follow in later disclosures are how Synergy CHC restructures its go-to-market approach for the UAE and Turkey and whether any financial statement impacts related to the previously recognized $2.9 million license fee are discussed in subsequent periodic reports for periods including 2026.

false 0001562733 0001562733 2026-02-27 2026-02-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2026

SYNERGY CHC CORP.

(Exact name of registrant as specified in its charter)

Nevada		001-42374		99-0379440
(State or Other Jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification No.)

865 Spring Street, Westbrook, Maine		04092
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (207) 321-2350

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		SNYR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On February 27, 2026, Synergy CHC Corp. (the “Company”) was notified by Gravity Pharma General Trading LLC (“Gravity”) that Gravity was terminating, ab initio, the Brand License Agreement, dated March 31, 2025, by and between the Company and Gravity (as amended by Amendment No. 1 to the Brand License Agreement, dated June 30, 2025, the “Brand License Agreement”).

The Brand License Agreement provided for an exclusive license to sell and market certain FOCUSfactor and Flat Tummy Co. products (the “Licensed IP”) in the United Arab Emirates and Turkey (the “Territory”) in exchange for an aggregate license fee of $2.9 million. The Company previously accounted for the license fee as revenue.

The Company continues to pursue the registration and marketing of the Licensed IP in the Territory.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 3, 2026
	SYNERGY CHC CORP.
	By:	/s/ Jack Ross
	Name:	Jack Ross
	Title:	Chief Executive Officer

2

FAQ

What did Synergy CHC Corp. disclose in this 8-K filing (SNYR)?

Synergy CHC Corp. disclosed that Gravity Pharma General Trading LLC terminated, ab initio, a Brand License Agreement covering FOCUSfactor and Flat Tummy Co. products in the UAE and Turkey. The company had previously recorded a $2.9 million license fee from this agreement as revenue.

Which products were covered by Synergy CHC’s terminated Brand License Agreement?

The terminated Brand License Agreement covered certain FOCUSfactor and Flat Tummy Co. products. These products were licensed on an exclusive basis for sale and marketing in the United Arab Emirates and Turkey, giving Gravity Pharma General Trading LLC rights to the specified intellectual property in those territories.

What was the value of the license fee under Synergy CHC’s agreement with Gravity Pharma?

The Brand License Agreement called for an aggregate license fee of $2.9 million. Synergy CHC previously accounted for this $2.9 million fee as revenue in its financial statements, reflecting the consideration received for granting exclusive rights in the specified territories.

Which territories were affected by the termination of Synergy CHC’s Brand License Agreement?

The termination affects rights to sell and market certain FOCUSfactor and Flat Tummy Co. products in the United Arab Emirates and Turkey. These countries together formed the agreement’s defined territory for the licensed intellectual property granted to Gravity Pharma General Trading LLC.

Is Synergy CHC Corp. abandoning the UAE and Turkey markets after this license termination?

Synergy CHC Corp. states it continues to pursue registration and marketing of the licensed products in the United Arab Emirates and Turkey. This indicates the company still views these territories as target markets, but will do so without the terminated Brand License Agreement with Gravity.

How had Synergy CHC previously accounted for the Brand License Agreement with Gravity?

Synergy CHC had previously accounted for the agreement’s aggregate $2.9 million license fee as revenue. This reflects recognition of the consideration related to granting exclusive rights for certain FOCUSfactor and Flat Tummy Co. products in the United Arab Emirates and Turkey under the Brand License Agreement.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB